ROCK1 and colorectal carcinoma: Although there is much more to explore, such as investigating the impact of targeted inhibition of IBA or blocking its binding with ROCK1 on immunotherapy, or further validating the predictive value of IBA levels in clinical immune checkpoint therapy, our results demonstrate that IBA hampers the immune response to CRC immunotherapy.